$AbbVie(ABBV)$AbbVie Inc. will present 23 abstracts at the 31st European Academy of Dermatology and Venerology (EADV) Congress in Milan, virtually and in-person, in September 2022. Data presented at the congress will provide dermatologic clinicians with studies and results regarding immune-mediated skin diseases such as psoriatic arthritis, psoriasis, atopic dermatitis, and vitiligo.1

Some of the most notable discussions will include data on:

The ongoing phase 3 active psoriatic arthritis clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the long-term efficacy and safety of risankizumab (SKYRIZI; Abbvie) for the treatment of psoriatic arthritis

Analyses from MEASURE-AD, a cross-sectional burden of disease study designed to identify global treatment patterns, healthcare resource utilization and costs, and the clinical and economic burden of moderate-to-severe atopic dermatitis (AD)

Data from VALUE, a 13-month interim analysis from a long-term, prospective observational study that has enrolled over 2,500 patients from 21 countries, evaluating the real-world efficacy, durability of response, and time to first treatment change for patients with moderate-to-severe psoriasis treated with risankizumab compared to other popular therapy options

Results from aIMM, a phase 3b, multicenter, interventional, open-label, single-arm study analyzing clinical efficacy, safety, and quality-of-life outcomes after 16 weeks of treatment for patients with psoriasis who were treated with risankizumab and previously achieved poor responses to one of 2 IL-17 inhibitors: secukinumab or ixekizumab

Interim analysis of the nearly 5-year (256 weeks) LIMMitless open-label extension study evaluating long-term efficacy and safety data with continuous risankizumab treatment in patients with moderate-to-severe plaque psoriasis

Two insurance claims database analyses examining economic and comorbidity impacts on patients with vitiligo

Overall, AbbVie will present 8 abstracts about risankizumab for psoriasis, 6 abstracts about risankizumab for psoriatic arthritis, and 3 abstracts about upadacitinib (RINVOQ; AbbVie) for atopic dermatitis. Regarding disease states, AbbVie will include 6 disease state abstracts covering psoriasis, atopic dermatitis, and vitiligo.